Literature DB >> 12899582

Vaccine adjuvant technology: from mechanistic concepts to practical applications.

Winfried G J Degen1, Theo Jansen, Virgil E J C Schijns.   

Abstract

Distinct types of immune responses are required for efficient elimination of different pathogens. Programming of the desired type of immune response by safe nonreplicating vaccines requires suitable vaccine adjuvants. Adjuvants largely determine the magnitude and quality of immune responses specific for the coadministered antigen. Unfortunately, rational vaccine design requiring a rational choice of vaccine adjuvant, is hampered by a lack of knowledge about the mechanism(s) of vaccine adjuvant activity. The current review addresses different critical immunological processes possibly explaining adjuvant functions. In addition, we discuss traditional vaccine adjuvant formulations and their possible mode of action. Finally, we reflect on the latest technologies for the identification of novel adjuvants using molecular analysis of immune activation and functional genomics.

Mesh:

Substances:

Year:  2003        PMID: 12899582     DOI: 10.1586/14760584.2.2.327

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  5 in total

1.  Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection.

Authors:  Denise Morais da Fonseca; Célio Lopes Silva; Marina Oliveira e Paula; Edson Garcia Soares; Gilles Marchal; Cynthia Horn; Vânia Luiza Deperon Bonato
Journal:  Immunology       Date:  2007-04-13       Impact factor: 7.397

2.  Immunogenicity of multi-epitope-based vaccine candidates administered with the adjuvant Gp96 against rabies.

Authors:  Yange Niu; Ye Liu; Limin Yang; Hongren Qu; Jingyi Zhao; Rongliang Hu; Jing Li; Wenjun Liu
Journal:  Virol Sin       Date:  2016-04-06       Impact factor: 4.327

3.  Aluminum hydroxide adjuvant differentially activates the three complement pathways with major involvement of the alternative pathway.

Authors:  Esin Güven; Karen Duus; Inga Laursen; Peter Højrup; Gunnar Houen
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

Review 4.  Novel adjuvants & delivery vehicles for vaccines development: a road ahead.

Authors:  Teena Mohan; Priyanka Verma; D Nageswara Rao
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375

5.  Forsythoside A Inhibits BVDV Replication via TRAF2-Dependent CD28-4-1BB Signaling in Bovine PBMCs.

Authors:  Quan-Jiang Song; Xiao-Gang Weng; Dong-Jie Cai; Wang Zhang; Jiu-Feng Wang
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.